Kat joined Cancer Research UK in 2004, after spending six years as a laboratory researcher. Kat loves talking about science, and regularly comments in the media on the latest discoveries as well as giving talks to staff and supporters. She has since left Cancer Research UK to pursue a career as a freelance journalist and science writer.
Olaparib is the first PARP inhibitor to move closer to licensing in Europe. What is it, how does it work, and when will it be available in the UK?
In 2001, our researchers Tim Hunt and Paul Nurse won a share of the Nobel prize for physiology or medicine. We look back at their achievements.
We speak to our pancreatic cancer expert Professor Andrew Biankin about how he’s trying to change the picture for people with the disease.
Triple negative breast cancer has poorer survival and is less well understood than other types, but research is making a difference.
Every year in the UK around 350 men are diagnosed with breast cancer, but because the disease is rare, it can be difficult to diagnose.
The new Environment and Health Atlas charts data about diseases such as cancer alongside environmental risk factors including pollution and pesticides.